Cargando…
Bioequivalence of twice-daily oral tacrolimus in transplant recipients: More evidence for consensus?
In this Perspective on the clinical trial by Rita Alloway and colleagues, Simon Ball explains the benefits to healthcare systems and individual patients of the bioequivalence established between generic and brand-name formulations of an immunosuppressive drug in transplant recipients.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685474/ https://www.ncbi.nlm.nih.gov/pubmed/29135980 http://dx.doi.org/10.1371/journal.pmed.1002429 |